The ruling could end years of US litigation against Bayer over claims that Roundup weedkiller causes cancer, a legal battle inherited from Monsanto
A US judge has approved a $7.25 billion settlement by German chemical and pharmaceutical giant Bayer over claims that Roundup weedkiller causes cancer. The deal could bring an end to years of costly litigation involving tens of thousands of lawsuits.
Missouri Judge Timothy Boyer granted final approval to the deal on Friday. The nationwide settlement includes people who developed non-Hodgkin lymphoma, a type of blood cancer allegedly linked to Roundup exposure, as well as those who could be diagnosed in the future if they were exposed before February 17, 2026.
Under the deal, Bayer will pay up to $7.25 billion into a compensation fund over 21 years. Individual payouts are expected to average $10,000 to $165,000 depending on the patient’s age, severity of illness, and duration of exposure.
Judge Boyer described the deal as “among the largest in [the] history of mass tort personal-injury class action settlements.” He rejected objections from lawyers who deemed the compensation inadequate, saying further delays could leave seriously ill claimants waiting years for payments. Bayer CEO Bill Anderson welcomed the ruling as “a decisive milestone” in the company’s struggle to mitigate the risks of Roundup litigation.
Read more Top US court to review suit against German chemicals giantBayer inherited the legal battle when it acquired US agricultural chemical giant Monsanto for $63 billion in 2018. The takeover gave it control of Roundup, one of the world’s most widely used herbicides, but also saddled it with mounting cancer litigation. Bayer currently faces around 65,000 claims in US courts.
Introduced by Monsanto in 1974, Roundup contains glyphosate, a chemical used to kill weeds without harming genetically modified crops designed to resist it. Monsanto was accused of failing to warn users about the alleged cancer risks. Bayer argued that the warnings would violate labeling requirements set by the US Environmental Protection Agency (EPA).
Read more Court throws out weedkiller maker's cancer damage appealAfter years of litigation, Bayer reached a preliminary settlement in February. In June, the US Supreme Court restricted lawsuits under state laws requiring additional cancer warnings, paving the way for approval.
The legal battle has already cost Bayer dearly. The company agreed to a $10.9 billion settlement in 2020, has spent at least $14 billion on Roundup litigation, and set aside around $16 billion for related legal costs. Its shares have fallen around 46% since the Monsanto takeover. Despite the ruling on Friday, around 200 cases remain pending in federal courts outside the settlement. The approval could also face appeals, delaying payments and prolonging the dispute.
READ MORE: EU to prolong authorization for controversial herbicide
The controversy over Roundup’s cancer risks remains unresolved. The World Health Organization’s cancer research agency classified glyphosate as ‘probably carcinogenic’ in 2015. While the EPA maintains that glyphosate is unlikely to cause cancer when used as directed, it has been reassessing its health risks since 2022. In September, it expanded the review with the Department of Health and Human Services. Findings are expected next year.
Despite insisting that Roundup is safe, Bayer has removed glyphosate from newer versions sold to US residential consumers, while retaining it in agricultural products.
Hence then, the article about us court greenlights bayer s 7 25 bn roundup cancer deal was published today ( ) and is available on Russia Today ( News ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( US court greenlights Bayer’s $7.25 bn Roundup cancer deal )
Also on site :
- 16 Years Before Robert Pattinson’s James Bond Casting, He Shared the Screen With Former 007 Pierce Brosnan
- ‘Al Hayba’ Star Taim Hasan To Play Syrian Whistleblower Farid Al-Madhhan In Neon-Backed ‘Caesar’ Biopic
- Robert Pattinson’s James Bond Movie ‘Talking About’ Shooting at U.K.’s Pinewood Studios, Director Says: ‘We’re the Home of Bond’